AIM ImmunoTech Inc.

Overview

Compare with EXOZYMES INC., Candel Therapeutics or VivoSim Labs, INC., or pick any stock.

• TickerAIM on NYSE¹
• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersOcala, Florida¹
• Incorporated inDE²
• Business address2117 Sw Highway 484, Ocala, Fl 32801²
• Filer categoryNon-accelerated filer, Smaller reporting company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Company’s research and development of Ampligen has included a variety of diseases and health matters:³ From its latest annual report

Corporate structure

AIM ImmunoTech Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What AIM ImmunoTech Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

Our principal executive and finance office is located at 2117 SW Highway 484, Ocala FL 34473, the human resource office is located at 604 Main Street, Riverton, NJ 08077 and manufacturing is located at 671A US-1 South, North Brunswick, NJ 08902. We currently lease our principal executive office and finance for $3,744 per month, our human resource office for $3,000 per month and our manufacturing office for $17,080 per month.

Item 2 of the 10-K filed Mar 27, 2026.³

Leadership

Who has led AIM ImmunoTech Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerThomas K. Equels Mar 10, 2016 to Jun 30, 2016¹²
• Chief executive officerAdam Pascale Jun 30, 2016 to Jun 30, 2016¹³
• PresidentThomas K. Equels Jun 10, 2016 to now¹⁴
• Chief financial officerEllen M. Lintal Sep 20, 2019 to Mar 4, 2022¹⁵
• Chief financial officerAdam Pascale Apr 6, 2016 to Jun 17, 2019¹⁶
• Chief financial officerThomas K. Equels Jun 11, 2014 to Aug 14, 2015¹⁷
• Chief financial officerCharles Thomas Bernhardt Iii. Mar 17, 2009 to Dec 22, 2011¹⁸
• Chief financial officerRobert E. Peterson Jan 17, 2007 to Mar 12, 2008¹⁹
• Chief operating officerPeter W. Rodino Iii. Dec 11, 2020 to now²⁰

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerRob Dickey named Feb 21, 2024⁴⁰
• Executive Officer, DirectorThomas Equals named Feb 21, 2024⁴⁰
• DirectorWilliam Mitchell named Feb 21, 2024⁴⁰

Former names

• HEMISPHERX BIOPHARMA INCSep 30, 1996 to Aug 26, 2019²

Timeline

1. Sep 14, 20268-K Entered a material agreement; Unregistered sale of shares⁴¹
2. Sep 10, 20268-K Entered a material agreement; Unregistered sale of shares⁴²
3. Sep 4, 20268-K Entered a material agreement; Ended a material agreement; Unregistered sale of shares⁴³
4. Aug 11, 20268-K Regulation FD disclosure⁴⁴
5. Aug 10, 20268-K Results of operations⁴⁵
6. Aug 6, 20268-K Entered a material agreement; Director nominations⁴⁶
7. Aug 5, 20268-K Ended a material agreement⁴⁷
8. Jul 16, 20268-K Shareholder vote⁴⁸
9. Jun 15, 20268-K Other events⁴⁹
10. Jun 11, 20268-K Entered a material agreement; Unregistered sale of shares; Other events⁵⁰
11. Jun 10, 20268-K Bylaws or fiscal year changed⁵¹
12. Jun 4, 20268-K Regulation FD disclosure⁵²
13. Jun 30, 2016New chief executive Adam Pascale becomes CEO¹³
14. Mar 10, 2016New chief executive Thomas K. Equels becomes CEO¹²

Calendar

Coming up

1. Nov 16, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.32) a share, on Nov 17, 2025.⁵³

When it reported results

1. Aug 10, 2026Reported quarterly or annual results⁴⁵
2. May 19, 2026Reported quarterly or annual results⁵⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

405 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 89 major events, 104 insider forms, 15 large holders, 2 private raises, 175 other. The latest 20:

1. Sep 30, 2026ARS EDGAR
2. Sep 30, 2026DEF 14A EDGAR
3. Sep 18, 20264 EDGAR
4. Sep 17, 20264 EDGAR
5. Sep 16, 20264 EDGAR
6. Sep 15, 20264 EDGAR
7. Sep 14, 20268-K EDGAR
8. Sep 10, 20268-K EDGAR
9. Sep 4, 20268-K EDGAR
10. Aug 11, 20268-K EDGAR
11. Aug 10, 20268-K EDGAR
12. Aug 7, 202610-Q EDGAR
13. Aug 6, 20268-K EDGAR
14. Aug 5, 20268-K EDGAR
15. Jul 16, 20268-K EDGAR
16. Jul 9, 2026S-8 EDGAR
17. Jun 25, 2026DEF 14A EDGAR
18. Jun 24, 2026424B3 EDGAR
19. Jun 23, 2026EFFECT EDGAR
20. Jun 18, 2026CORRESP EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

37 open-market trades by officers, directors and large owners since October 2021: 36 buys and 1 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• INTRACOASTAL CAPITAL, LLCSCHEDULE 13G, 1 filing May 27, 2026⁵⁵
• Orca Capital AGSCHEDULE 13G, 1 filing May 12, 2026⁵⁶
• ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 14, 2025⁵⁷
• Todd DeutschSCHEDULE 13D/A, 11 filings Jul 27, 2023 to Dec 23, 2024⁵⁸

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Feb 16, 2024Raised $3.3 million in a private offering of debt Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How AIM ImmunoTech Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARAIM ImmunoTech Inc.¹
• CIK0000946644
• Employer ID (EIN)52-0845822³
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address2117 Sw Highway 484, Ocala, FL 32801¹
• Phone352-448-7797¹
• Shares outstanding30,442,139 as of Aug 7, 2026¹¹
• Public float$6.4M as of Jun 30, 2025³
• AuditorBDO USA, P.C., Miami, Florida PCAOB ID 243; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceMay 14, 1996¹
• Filings1,628 in all: 4 (546), 8-K (322), 10-Q (92), CORRESP (53), DEFA14A (51), 424B5 (44), UPLOAD (41), 424B3 (36)¹
  All 57 form types

  10-K (30), DEF 14A (30), 5 (29), EFFECT (26), DFAN14A (25), S-1 (20), S-1/A (18), S-3 (17), 3 (15), 4/A (15), S-8 (15), 10-K/A (14), PRE 14A (14), S-3/A (14), SC 13G (14), 10-Q/A (13), 8-K/A (12), SC 13G/A (11), SC 13D/A (10), CT ORDER (8), POS AM (8), DEFR14A (7), NT 10-Q (7), DEFC14A (6), NT 10-K (6), PREC14A (6), PRER14A (6), 424B1 (5), REGDEX (5), D (4), 424B4 (3), 8-A12B/A (3), SC 13D (3), 25 (2), 5/A (2), 8-A12B (2), ARS (2), PRRN14A (2), RW (2), S-8 POS (2), SCHEDULE 13G (2), 8-A12G (1), 8-A12G/A (1), AW (1), CERTNYS (1), D/A (1), NT 10-K/A (1), SCHEDULE 13D/A (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Mar 27, 2026
  Quarterly report (10-Q) Aug 7, 2026
  Proxy statement (DEF 14A) Sep 30, 2026
  Latest 8-K (8-K) Sep 14, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks AIM ImmunoTech Inc. names in Item 1A of its 10-K filed Mar 27, 2026: 43 risks under these headings, as written.³

• Risks Related to Ownership of Our Securities
• We have a history of losses, expect to continue to incur losses in the near term and may not achieve or sustain profitability in the future, and as a result, there is a substantial doubt about our ability to continue as a going concern.
• We are currently not in compliance with the Exchange continued listing requirements. If we are unable to regain compliance with the Exchange’s listing requirements, our securities could be delisted, which could affect our common stock market price and liquidity and reduce our ability to raise capital.
• If we are not able to comply with the applicable continued listing requirements or standards of the NYSE American, our common stock could be delisted from the Exchange.
• We may seek to raise additional funds or develop strategic relationships by issuing securities that would dilute your ownership. Depending on the terms available to us, if these activities result in significant dilution, it may negatively impact the trading price of our common stock.
• An active, liquid and orderly trading market for our common stock may not develop, the price of our stock may be volatile, and you could lose all or part of your investment.
• If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.
• If we were to dissolve, the holders of our securities may lose all or substantial amounts of their investments.
• If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our securities adversely, our stock price and trading volume could decline.
• We are a smaller reporting company, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
• Risks Associated with Our Business
• We will require additional financing which may not be available.

Legal proceedings

Jorgl v. AIM ImmunoTech, Inc. et al., C.A. No. 2022-0669-LWW (Del. Ch.)

On July 29, 2022, Jonathan Jorgl (“Jorgl”) filed a complaint against the Company and the then-members of its Board of Directors, Thomas Equels, William Mitchell, and Stewart Appelrouth, in the Delaware Court of Chancery (the “Jorgl Action”). The complaint challenged the decision of the Company’s Board of Directors to reject Jorgl’s notice of intent to nominate two candidates for election to the Company’s Board of Directors on the basis that the notice failed to comply with the Company’s bylaws. The Complaint sought a declaration that Jorgl’s nomination was valid and effective and complied with the bylaws and that the Company must list Jorgl’s candidates in its proxy materials, as well as a temporary restraining order, preliminary injunction, and permanent injunction enjoining defendants from taking any action to prevent Jorgl from exercising his alleged nomination rights and from making any statements that disparage Jorgl’s candidates prior to or during the Company’s annual meeting of stockholders.

The opening of Item 3, Legal Proceedings.³